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Characterization 
of Mycobacterium 
orygis
To the Editor: In a recently 
published study, van Ingen et 
al. (1) described the molecular 
characterization and phylogenetic 
position of the oryx bacillus, a 
member of the Mycobacterium 
tuberculosis complex, and proposed a 
long overdue name for the organism: 
Mycobacterium orygis. The authors 
described oryx bacillus as a separate 
taxon; the aim was for this description 
to be used in the future to identify 
the subspecies. Thus, we thought 
it pertinent to provide additional 
information that would be useful in 
speciating isolates of the oryx bacillus.
In a recent study, we genotyped an 
isolate of oryx bacillus obtained from 
an African buffalo in South Africa (2). 
This isolate was typed by using 16S 
rDNA, M. tuberculosis complex–
specifi c multiplex-PCR, regions-of-
difference analyses, gyrase B gene 
single nucleotide polymorphism 
(SNP) analysis, spoligotyping, and 
mycobacterial interspersed repetitive 
units–variable number tandem repeat 
typing. We showed that, in addition to 
the markers described by van Ingen et 
al. (1), regions of difference 701 and 
702 were also intact in M. orygis.
In addition, van Ingen et al. 
identifi ed the Rv204238 GGC mutation 
as a novel, useful genetic marker to 
identify M. orygis. However, such a 
marker already exists in the form of 
the very specifi c gyrBoryx G to A SNP 
at position 1113, which was described 
by Huard et al. (3). On its own, SNP 
detection in the gyrB gene allows 
differentiation of at least 6 of the 9 
M. tuberculosis complex species from 
each other (M. canettii, M. tuberculosis, 
M. orygis, M. microti, M. caprae, and 
M. bovis) (3). Thus, the SNP at position 
1113 is more useful than the Rv204238 
mutation as a novel and distinct genetic 
marker to identify M. orygis.
Apart from this, we found that 
the sequence type (ST) 587 was not 
the only spoligotype specifi c for M. 
orygis. In our study, the variant type 
ST701 (annotated as M. africanum in 
the spolDB4 database) (4) is also an 
M. orygis–specifi c type and exactly 
matches that of a previous isolate of 
the oryx bacillus (SB0319) from the 
M. bovis spoligotype database (5). 
This spoligotype differs from ST587 
by the presence of spacer 18, and 
the spoligotype was not found in the 
extensive sample set of van Ingen et 
al. (1).
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Epsilonproteo-
bacteria in 
Humans, 
New Zealand
To the Editor: Cornelius et 
al. (1) addressed the potential of 
Campylobacter ureolyticus as an 
emerging pathogen by conducting 
a molecular study on 128 diarrheal 
specimens and 49 fecal samples 
from healthy volunteers. Reporting 
the identifi cation of C. ureolyticus in 
12 (24.5%) of 49 healthy volunteers, 
a number that they compared with 
our fi nding of 349 (23.8%) from 
Campylobacter spp.–positive samples 
(2), the authors concluded that C. 
ureolyticus species “are unlikely 
causes of diarrhea,” an assertion with 
which we take issue.
This interpretation does not 
take into account that our screening 
involved 7,194 symptomatic patients: 
a sample size 40× greater than that of 
Cornelius et al. In this context, the 
likely carriage rate for C. ureolyticus 
is 1.15%. Also, our assay, which has 
a limit of detection in the picomolar 
range, is likely comparable with, if 
not greater than, that of Cornelius et 
al. (1).
Accounting for variations in 
geographic location and detection 
methods, a detection rate of 24.5% in 
healthy volunteers (overall detection 
rate 14.7%) is high in contrast to our 
reported rate of 1.15%. One possible 
explanation for this discrepancy 
is that Cornelius et al. “did not 
specifi cally exclude volunteers who 
had had gastrointestinal disturbances 
in the 10 days before sampling,” 
Campylobacter can be shed in 
feces for <4 weeks after infection. 
Also, Cornelius et al. (1) noted the 
possibility of “genetically distinct 
but phenotypically indistinguishable 
genomospecies differing in their 
pathogenic potential” to account 
for the presence of the emerging 
pathogen C. concisus in healthy 
volunteers and patients with diarrheal 
illness. This may also apply for C. 
ureolyticus.
We reported a strong seasonal 
prevalence of C. ureolytcius and a 
bimodal age distribution (2). The 
lack of any related details from 
Cornelius et al. may undermine their 
reported detection rates. These factors 
strongly suggest that the statement, 
“these species are unlikely causes of 
diarrhea,” should, at the very least, be 
taken under advisement.
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In Response: In response to the 
letter by Bullman et al. (1), a major as-
pect of our study (2) was to compare 
epsilonproteobacterial populations in 
healthy persons and those who have 
diarrhea. We have not examined as 
many diarrheal samples as Bullman et 
al. (3). However, in contrast with their 
study, we have examined samples 
from persons with no evident disease 
manifestations. Because the presence 
of an agent during disease is not proof 
of causation, we believed that a base-
line for comparison was needed. Cam-
pylobacter ureolyticus was found in 
a greater proportion of samples from 
healthy persons (24%) than samples 
from persons who had diarrhea (11%) 
(p = 0.041, by χ2 test). 
Samples from healthy persons 
were tested on 2 occasions: 18 sam-
ples in September 2007 (New Zea-
land spring) at the Institute of En-
vironmental Science and Research, 
Christchurch, in the  workplace, and 
31 samples in June 2009 (New Zea-
land winter), at Christchurch Hospi-
tal under the guidance of a clinician. 
We have no reason to believe any of 
the workplace samples were provided 
when volunteers had diarrhea, par-
ticularly considering our workplace 
guidelines and staff characteristics. 
In each testing round, 6 fecal samples 
had positive test results for C. ureo-
lyticus. These periods equate to the 
peak and trough periods described by 
Bullman et al. (3). We were unable to 
provide many details regarding sam-
pling in our paper because of space 
constraints.
Considering our baseline com-
parisons of healthy persons with those 
who had diarrhea, we affi rm our con-
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